The work could facilitate the rapid screening of many drugs, infectious diseases, and cancers in under five minutes.
Prof Alexis Vallée-Bélisle of the University of Montreal Department of Chemistry has worked with Prof Francesco Ricci of the University of Rome Tor Vergata and Prof Kevin W. Plaxco of the University of California at Santa Barbara to improve a new biosensing nanotechnology. The results of the study were recently published in the Journal of American Chemical Society (JACS).
‘Nature is a continuing source of inspiration for developing new technologies,’ said Prof Francesco Ricci in a statement. ‘Many scientists are currently working to develop biosensor technology to detect - directly in the bloodstream and in seconds - drug, disease, and cancer molecules.’
‘The most recent rapid and easy-to-use biosensors developed by scientists to determine the levels of various molecules such as drugs and disease markers in the blood only do so when the molecule is present in a certain concentration, called the concentration window,’ said Professor Vallée-Bélisle. ‘Below or above this window, current biosensors lose much of their accuracy.’
To overcome this limitation, the international team looked to nature.
‘In cells, living organisms often use inhibitor or activator molecules to automatically program the sensitivity of their receptors (sensors), which are able to identify the precise amount of thousand of molecules in seconds,’ said Prof Vallée-Bélisle. ‘We therefore decided to adapt these inhibition, activation, and sequestration mechanisms to improve the efficiency of artificial biosensors.’
The researchers put their idea to the test by using an existing cocaine biosensor and revising its design so that it would respond to a series of inhibitor molecules.
They were able to adapt the biosensor to respond optimally even with a large concentration window.
‘What is fascinating,’ said Alessandro Porchetta, a doctoral student at the University of Rome, ‘is that we were successful in controlling the interactions of this system by mimicking mechanisms that occur naturally.’
‘Besides the obvious applications in biosensor design, I think this work will pave the way for important applications related to the administration of cancer-targeting drugs, an area of increasing importance,’ said Prof Plaxco. ‘The ability to accurately regulate biosensor or nanomachine’s activities will greatly increase their efficiency.’
Oxa launches autonomous Ford E-Transit for van and minibus modes
I'd like to know where these are operating in the UK. The report is notably light on this. I wonder why?